Cumming Global Centre for Pandemic Therapeutics Foundation Grants open globally
Posted: 26 October 2023 Grant applications are being sought by the Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre) for Round Two of its Foundation Grants program, which is offering a pool of up to AU$5 million in…
AD-214 PHASE I EXTENSION: FAVOURABLE TOLERABILITY AFTER THIRD DOSE
Posted: 26 October 2023 AdAlta Limited (ASX:1AD), the clinical stage company developing novel protein and cell therapeutic products from its i-body® platform, is pleased to report that all healthy volunteers in its AD-214 Phase I extension study have…
Victorian Medical Research Acceleration Fund
Posted: 26 October 2023 Closes: 1 December 2023 The Victorian Medical Research Acceleration Fund (the VMRAF) was first launched by the Victorian Government in 2017. The VMRAF is designed to capitalise on Victoria’s competitive advantages in research, increase…
Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancers
Posted: 23 October 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® cabazitaxel…
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Posted: 23 October 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces excellent new clinical data from the TACTI-002 / KEYNOTE-798…
A better ‘map’ of the lights you see when you close your eyes can improve ‘bionic eye’ outcomes
Posted: 17 October 2023 Researchers at Monash University have identified a new way of mapping ‘phosphenes’ – the visual perception of the bright flashes we see when no light is entering the eye – to improve the outcome…
New $15m frontier technology centre to develop next-generation cancer drugs
Posted: 17 October 2023 Australia has a new frontier technology centre that is set to revolutionise drug development for metastatic prostate cancer and childhood neuroblastoma. The Australian Centre for Targeted Therapeutics (ACTT) has been awarded $15 million from…
A well-established drug can improve hand osteoarthritis symptoms: study
Posted: 17 October 2023 Relief could be on the way for people with painful hand osteoarthritis after a Monash University and Alfred Health-led study found an affordable existing drug can help. Until now there has been no effective…
Australian-first trial to transform lives of children with a severe immune deficiency disorder
Posted: 17 October 2023 A cure for a severe immune deficiency disorder in children that makes them extremely vulnerable to infections will be offered in Australia for the first time under a cutting-edge gene therapy trial. Murdoch Children’s…
Melbourne invention brings new hope for rheumatoid arthritis
Posted: 17 October 2023 A new nerve treatment invented by Melbourne researchers at the Bionics Institute is bringing hope to people with rheumatoid arthritis. The tiny piece of ground-breaking technology – the size of a thumbnail – could…
Global non-profit CARB-X awards more than AUD$2.6 million to University of Melbourne’s Doherty Institute to fight antibiotic resistance
Posted: 17 October 2023 University of Melbourne researchers from the Peter Doherty Institute for Infection and Immunity (Doherty Institute) are developing a world-first treatment for antibiotic-resistant community-acquired bacterial pneumonia (CABP). The AUD$2.68M (US$1.75M) award by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator…
Cartherics appoints new Chief Scientific Officer
Posted: 17 October 2023 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately.…
